Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.
- 1 January 1999
- journal article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 16 (7), 1059-1066
- https://doi.org/10.1023/a:1018939900961
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.The Journal of Experimental Medicine, 1996
- Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseasesImmunology Today, 1995
- Prevention of Autoimmune Diabetes in Nonobese Diabetic Female Mice by Treatment with Recombinant Glutamic Acid Decarboxylase (GAD 65)Clinical Immunology and Immunopathology, 1995
- Epitope specificity, cytokine production profile and diabetogenic activity of insulin‐specific T cell clones isolated from NOD miceEuropean Journal of Immunology, 1995
- Oral Administration of Human Insulin to NOD Mice Generates CD4+ T Cells that Suppress Adoptive Transfer of DiabetesJournal of Autoimmunity, 1994
- Immunoregulatory and Cytokine Imbalances in the Pathogenesis of IDDM: Therapeutic Intervention by Immunostimulation?Diabetes, 1994
- Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetesNature, 1993
- Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.JCI Insight, 1993
- Monoclonal antibody-mediated cytotoxicity against rat Beta cells detected in vitro does not cause Beta-cell destruction in vivoDiabetologia, 1992
- Monoclonal antibodies to glutamic acid decarboxylase.Proceedings of the National Academy of Sciences of the United States of America, 1986